Dorzolamide

Generic Name: Dorzolamide hydrochloride
Dosage Form: ophthalmic solution

Dorzolamide Hydrochloride Ophthalmic Solution
Ophthalmic Solution 2%

Dorzolamide Description

Dorzolamide hydrochloride (Dorzolamide hydrochloride ophthalmic solution) is a carbonicanhydrase inhibitor formulated for topical ophthalmic use.

Dorzolamide hydrochloride is described chemically as: (4S-trans)-4-(ethylamino)-5,6-dihydro- 6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride.Dorzolamide hydrochloride is optically active. The specific rotation is:

Slideshow: 2013 Drug News Round-Up: Top 20 Stories

[a] 25° (C=1, water) = ~ -17°
   .405

Its empirical formula is C10H16N2O4S3•HCl and its structural formula is:

Dorzolamide hydrochloride has a molecular weight of 360.9 and a melting point of about 264°C. It is a white to off-white, crystalline powder, which is soluble in water and slightly soluble in methanol and ethanol.

Dorzolamide hydrochloride Ophthalmic Solution is supplied as a sterile, isotonic, buffered,slightly viscous, aqueous solution of Dorzolamide hydrochloride. The pH of the solution is approximately 5.6, and the osmolarity is 260-330 mOsM. Each mL of Dorzolamide hydrochloride 2% contains 20 mg Dorzolamide (22.3 mg of Dorzolamide hydrochloride).Inactive ingredients are hydroxyethyl cellulose, mannitol, sodium citrate dihydrate, sodium hydroxide (to adjust pH) and water for injection. Benzalkonium chloride 0.0075% is added as a preservative.

Dorzolamide - Clinical Pharmacology

Mechanism of Action
Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye.It catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number ofisoenzymes, the most active being carbonic anhydrase II (CA-II), found primarily in red bloodcells (RBCs), but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation ofbicarbonate ions with subsequent reduction in sodium and fluid transport. The result is areduction in intraocular pressure (IOP).

Dorzolamide hydrochloride Ophthalmic Solution contains Dorzolamide hydrochloride, aninhibitor of human carbonic anhydrase II. Following topical ocular administration, Dorzolamide hydrochloride reduces elevated intraocular pressure. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.

Pharmacokinetics/Pharmacodynamics
When topically applied, Dorzolamide reaches the systemic circulation. To assess the potentialfor systemic carbonic anhydrase inhibition following topical administration, drug andmetabolite concentrations in RBCs and plasma and carbonic anhydrase inhibition in RBCswere measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of binding to CA-II. The parent drug forms a single N-desethyl metabolite, which inhibits CA-IIless potently than the parent drug but also inhibits CA-I. The metabolite also accumulates inRBCs where it binds primarily to CA-I. Plasma concentrations of Dorzolamide and metabolite are generally below the assay limit of quantitation (15nM). Dorzolamide binds moderately to plasma proteins (approximately 33%). Dorzolamide is primarily excreted unchanged in the urine; the metabolite also is excreted in urine. After dosing is stopped, Dorzolamide washes out of RBCs nonlinearly, resulting in a rapid decline of drug concentration initially, followed by a slower elimination phase with a half-life of about four months.

To simulate the systemic exposure after long-term topical ocular administration, Dorzolamidewas given orally to eight healthy subjects for up to 20 weeks. The oral dose of 2 mg b.i.d.closely approximates the amount of drug delivered by topical ocular administration of Dorzolamide hydrochloride 2% t.i.d. Steady state was reached within 8 weeks. The inhibition of CA-II and total carbonic anhydrase activities was below the degree of inhibition anticipated to be necessary for a pharmacological effect on renal function and respiration in healthy individuals.

Clinical Studies
The efficacy of Dorzolamide hydrochloride was demonstrated in clinical studies in the treatment of elevated intraocular pressure in patients with glaucoma or ocular hypertension (baseline IOP ≥ 23 mmHg). The IOP-lowering effect of Dorzolamide hydrochloride was approximately 3 to 5 mmHg throughout the day and this was consistent in clinical studies of up to one year duration.

The efficacy of Dorzolamide hydrochloride when dosed less frequently than three times a day (alone or in combination with other products) has not been established.

In a one year clinical study, the effect of Dorzolamide hydrochloride 2% t.i.d. on the corneal endothelium was compared to that of betaxolol ophthalmic solution b.i.d. and timolol maleate ophthalmic solution 0.5% b.i.d. There were no statistically significant differences between group sin corneal endothelial cell counts or in corneal thickness measurements. There was a mean loss of approximately 4% in the endothelial cell counts for each group over the one year period.

Indications and Usage for Dorzolamide

Dorzolamide hydrochloride Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Contraindications

Dorzolamide hydrochloride is contraindicated in patients who are hypersensitive to any component of this product.

Warnings

Dorzolamide hydrochloride is a sulfonamide and, although administered topically, is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration with Dorzolamide hydrochloride. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis,aplastic anemia, and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.

Precautions

General

The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. Dorzolamide hydrochloride has not been studied in patients with acute angle-closure glaucoma.

Dorzolamide hydrochloride has not been studied in patients with severe renal impairment (CrCl< 30 mL/min). Because Dorzolamide hydrochloride and its metabolite are excreted predominantly by the kidney, Dorzolamide hydrochloride is not recommended in such patients.

Dorzolamide hydrochloride has not been studied in patients with hepatic impairment and should therefore be used with caution in such patients.

In clinical studies, local ocular adverse effects, primarily conjunctivitis and lid reactions, were reported with chronic administration of Dorzolamide hydrochloride. Many of these reactions had the clinical appearance and course of an allergic-type reaction that resolved upon discontinuation of drug therapy. If such reactions are observed, Dorzolamide hydrochloride should be discontinued and the patient evaluated before considering restarting the drug. (See ADVERSE REACTIONS.)

There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and Dorzolamide hydrochloride. The concomitant administration of Dorzolamide hydrochloride and oral carbonic anhydrase inhibitors is not recommended.

There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g., Dorzolamide) after filtration procedures.

There is an increased potential for developing corneal edema in patients with low endothelial cell counts. Precautions should be used when prescribing Dorzolamide hydrochloride to this group.

Information for Patients

Dorzolamide hydrochloride is a sulfonamide and although administered topically is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration. Patients should be advised that if serious or unusual reactions including severe skin reactions or signs of hypersensitivity occur, they should discontinue the use of the product (see WARNINGS).

Patients should be advised that if they develop any ocular reactions, particularly conjunctivitis and lid reactions, they should discontinue use and seek their physician’s advice.

Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.

Patients should also be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Patients also should be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician’s advice concerning the continued use of the present multidose container.

If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.

Patients should be advised that Dorzolamide hydrochloride contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following Dorzolamide hydrochloride administration.

Drug Interactions

Although acid-base and electrolyte disturbances were not reported in the clinical trials with Dorzolamide hydrochloride, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving Dorzolamide hydrochloride.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a two-year study of Dorzolamide hydrochloride administered orally to male and female Sprague-Dawley rats, urinary bladder papillomas were seen in male rats in the highest dosage group of 20 mg/kg/day (250 times the recommended human ophthalmic dose). Papillomas were not seen in rats given oral doses equivalent to approximately 12 times the recommended human ophthalmic dose. No treatment-related tumors were seen in a 21-month study in female and male mice given oral doses up to 75 mg/kg/day (~900 times the recommended human ophthalmic dose).

The increased incidence of urinary bladder papillomas seen in the high-dose male rats is a class effect of carbonic anhydrase inhibitors in rats. Rats are particularly prone to developing papillomas in response to foreign bodies, compounds causing crystalluria, and diverse sodium salts.

No changes in bladder urothelium were seen in dogs given oral Dorzolamide hydrochloride for one year at 2 mg/kg/day (25 times the recommended human ophthalmic dose) or monkeys dosed topically to the eye at 0.4 mg/kg/day (~5 times the recommended human ophthalmic dose) for one year.

The following tests for mutagenic potential were negative: (1) in vivo (mouse) cytogenetic assay; (2) in vitro chromosomal aberration assay; (3) alkaline elution assay; (4) V-79 assay; and (5) Ames test.

In reproduction studies of Dorzolamide hydrochloride in rats, there were no adverse effects on the reproductive capacity of males or females at doses up to 188 or 94 times, respectively, the recommended human ophthalmic dose.

Pregnancy: Teratogenic Effects: Pregnancy Category C.

Teratogenic Effects. Pregnancy Category C. Developmental toxicity studies with Dorzolamide hydrochloride in rabbits at oral doses of ≥ 2.5 mg/kg/day (31 times the recommended human ophthalmic dose) revealed malformations of the vertebral bodies. These malformations occurred at doses that caused metabolic acidosis with decreased body weight gain in dams and decreased fetal weights. No treatment-related malformations were seen at 1.0 mg/kg/day(13 times the recommended human ophthalmic dose). There are no adequate and well controlledstudies in pregnant women. Dorzolamide hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

In a study of Dorzolamide hydrochloride in lactating rats, decreases in body weight gain of 5 to 7% in offspring at an oral dose of 7.5 mg/kg/day (94 times the recommended human ophthalmic dose) were seen during lactation. A slight delay in postnatal development (incisor eruption, vaginal canalization and eye openings), secondary to lower fetal body weight, was noted.

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Dorzolamide hydrochloride, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and IOP-lowering effects of Dorzolamide hydrochloride have been demonstrated in pediatric patients in a 3-month, multicenter, double-masked, active-treatment-controlled trial.

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Adverse Reactions

Controlled clinical trials: The most frequent adverse events associated with Dorzolamide hydrochloride were ocular burning, stinging, or discomfort immediately following ocular administration (approximately one-third of patients). Approximately one-quarter of patients noted a bitter taste following administration. Superficial punctate keratitis occurred in 10-15% of patients and signs and symptoms of ocular allergic reaction in approximately 10%. Events occurring in approximately 1-5% of patients were conjunctivitis and lid reactions (see PRECAUTIONS, General), blurred vision, eye redness, tearing, dryness, and photophobia. Other ocular events and systemic events were reported infrequently, including headache, nausea, asthenia/fatigue; and, rarely, skin rashes, urolithiasis, and iridocyclitis.

In a 3-month, double-masked, active-treatment-controlled, multicenter study in pediatric patients, the adverse experience profile of Dorzolamide hydrochloride was comparable to that seen in adult patients.

Clinical practice: The following adverse events have occurred either at low incidence (<1%) during clinical trials or have been reported during the use of Dorzolamide hydrochloride inclinical practice where these events were reported voluntarily from a population of unknown size and frequency of occurrence cannot be determined precisely. They have been chosen for inclusion based on factors such as seriousness, frequency of reporting, possible causal connection to Dorzolamide hydrochloride, or a combination of these factors: signs and symptoms of systemic allergic reactions including angioedema, bronchospasm, pruritus, andurticaria; Stevens-Johnson syndrome and toxic epidermal necrolysis; dizziness, paresthesia; ocular pain, transient myopia, choroidal detachment following filtration surgery, eyelid crusting; dyspnea; contact dermatitis, epistaxis, dry mouth and throat irritation.

Overdosage

Electrolyte imbalance, development of an acidotic state, and possible central nervous system effects may occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.

Dorzolamide Dosage and Administration

The dose is one drop of Dorzolamide Hydrochloride Ophthalmic Solution in the affected eye(s) three times daily.

Dorzolamide hydrochloride may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.

How is Dorzolamide Supplied

Dorzolamide hydrochloride Ophthalmic Solution is a slightly opalescent, nearly colorless, slightly viscous solution.

Dorzolamide Hydrochloride Ophthalmic Solution is supplied in a 10mL white, round low densitypolyethylene (LPDE) bottle, with a natural LPDE dropper tip, and orange colored high-density polyethylene (HPDE) eyedropper cap. A white tamper evident overcap is provided. Dorzolamide Hydrochloride Ophthalmic Solution is available as follows:

NDC 47781-135-34, 10 mL

Storage:
Store Dorzolamide Hydrochloride Ophthalmic Solution at 20-25°C (68-77°F) [See USP Controlled Room Temperature]. Protect from light.

Rx only

Distributed by:
Alvogen, Inc
Pine Brook, NJ 07058 USA

MADE IN USA

PI135-00
Rev. 07/2013

PATIENT MEDICATION INFORMATION SECTION

Dorzolamide Hydrochloride Ophthalmic Solution
Ophthalmic Solution 2%

INSTRUCTIONS FOR USE

Please follow these instructions carefully when using Dorzolamide Hydrochloride Ophthalmic Solution. Use Dorzolamide Hydrochloride Ophthalmic Solution as prescribed by your doctor.

1. If you use other topically applied ophthalmic medications, they should be administered at least 10 minutes before or after Dorzolamide Hydrochloride Ophthalmic Solution.
2. Wash hands before each use.
3. Before using the medication for the first time, be sure the white winged tamper evident overcap around cap is unbroken.
4. Remove the white overcap by turning it in a clockwise direction and discard.
5. To open the bottle, unscrew the cap by turning counterclockwise.
6. Tilt your head back and pull your lower eyelid down slightly to form a pocket between your eyelid and your eye.

7. Invert the bottle, and press lightly with the thumb or index finger until a single drop is dispensed into the eye as directed by your doctor.

DO NOT TOUCH YOUR EYE OR EYELID WITH THE DROPPER TIP. OPHTHALMIC MEDICATIONS, IF HANDLED IMPROPERLY, CAN BECOME CONTAMINATED BY COMMON BACTERIA KNOWN TO CAUSE EYE INFECTIONS. SERIOUS DAMAGE TO THE EYE AND SUBSEQUENT LOSS OF VISION MAY RESULT FROM USING CONTAMINATED OPHTHALMIC MEDICATIONS. IF YOU THINK YOUR MEDICATION MAY BE CONTAMINATED, OR IF YOU DEVELOP AN EYE INFECTION, CONTACT YOUR DOCTOR IMMEDIATELY CONCERNING CONTINUED USE OF THIS BOTTLE.

8. Repeat steps 6 & 7 with the other eye if instructed to do so by your doctor.
9. Replace the cap by turning until it is firmly touching the bottle. Do not overtighten the cap.
10. The dispenser tip is designed to provide a pre-measured drop; therefore, do NOT enlarge the hole of the dispenser tip.
11. After you have used all doses, there will be some Dorzolamide Hydrochloride Ophthalmic Solution left in the bottle. You should not be concerned since an extra amount of Dorzolamide Hydrochloride Ophthalmic Solution has been      added and you will get the full amount of Dorzolamide Hydrochloride Ophthalmic Solution that your doctor prescribed.Do not attempt to remove excess medicine from the bottle.

WARNING: Keep out of reach of children.

Call your doctor for medical advice about side effects. You may report side effects to Alvogen at 1-866-770-3024 or FDA at 1-800-FDA-1088. If you have any questions about the use of Dorzolamide Hydrochloride Ophthalmic Solution, please consult your doctor.

Made in USA

Distributed by:
Alvogen, Inc
Pine Brook, NJ 07058 USA

PI135-00
Rev. 07/2013

Dorzolamide HYDROCHLORIDE OPHTHALMIC SOLUTION 2%, 10ML   OPHTHALMIC SOLUTION 2%, 10ML
Dorzolamide hydrochloride ophthalmic solution 2%, 10ml solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:47781-135
Route of Administration OPHTHALMIC DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Dorzolamide HYDROCHLORIDE (Dorzolamide) Dorzolamide 22.3 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
HYDROXYETHYL CELLULOSE (100 MPA.S AT 2%)  
MANNITOL  
TRISODIUM CITRATE DIHYDRATE  
SODIUM HYDROXIDE  
BENZALKONIUM CHLORIDE  
WATER  
Packaging
# Item Code Package Description
1 NDC:47781-135-34 1 VIAL in 1 CARTON
1 10 mL in 1 VIAL
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA091034 12/16/2013
Labeler - ALVOGEN INC. (008057330)
Registrant - ZACH SYSTEM SPA (517259979)
Establishment
Name Address ID/FEI Operations
CATALENT PHARMA SOLUTIONS, LLC 043911403 manufacture(47781-135), pack(47781-135)
Revised: 12/2013
 
ALVOGEN INC.
Hide
(web5)